Bioidentical hormones vs standard HRT: what is the difference?

Short answer

• “Bioidentical” hormones are molecules that have the same chemical structure as human hormones (for example, 17β‑estradiol or micronized progesterone). “Standard” HRT usually refers to FDA‑approved hormone therapies that may be either chemically identical (some are) or synthetic/animal‑derived (some are not). The important practical difference is regulatory status and evidence: FDA‑approved products have standardized dosing and clinical trial data; many compounded “bioidentical” preparations do not.

What people mean by each term

• Bioidentical hormones: same molecular structure as endogenous hormones (e.g., estradiol, micronized progesterone). These may be available as FDA‑approved products (standardized pills, patches, gels) or made as customized compounded prescriptions by compounding pharmacies.
• Standard HRT: commonly refers to widely used, FDA‑approved estrogen and progestin products. Some of these are bioidentical (estradiol formulations) and some are not (e.g., conjugated equine estrogens, synthetic progestins).

Key differences (practical)

• Chemistry: Bioidentical = identical molecular structure to human hormones. Standard HRT can be bioidentical or non‑bioidentical (e.g., Premarin ≠ human estradiol; medroxyprogesterone acetate ≠ progesterone).
• Regulation and quality control: FDA‑approved products have consistent dosing, manufacturing standards, and clinical trial data. Compounded bioidentical products are not FDA‑approved and can vary in dose, purity and consistency.
• Evidence base: The safety and benefit profiles are best defined for FDA‑approved products. Claims that compounded bioidentical hormones are safer or more effective have not been proven.
• Testing and personalization: Some practitioners use saliva testing or customized dosing with compounded hormones. Major societies note saliva testing is unreliable for dosing and symptom control should guide therapy, not routine salivary hormone levels.

Safety and effectiveness

• Both types (when biologically active estrogen and appropriate progestogen are given) can relieve menopausal symptoms and prevent bone loss.
• Risks (blood clots, stroke, heart disease, breast cancer risk changes) depend on factors such as the type of estrogen, whether a progestogen is used, dose, route (oral vs transdermal), timing since menopause, and individual risk factors.
• Current guidance: use the lowest effective dose for the shortest needed time, individualize choice (transdermal estradiol may carry lower clot risk than some oral estrogens), and use FDA‑approved products when possible.

Examples of products and why (for discussion with your clinician)

• Estradiol patch: Vivelle‑Dot, Climara, Alora — FDA‑approved transdermal estradiol with standardized dosing; transdermal route may have lower VTE risk than oral in some patients.
• Oral estradiol: Estrace (estradiol) — an FDA‑approved form of bioidentical estradiol.
• Micronized progesterone: Prometrium — FDA‑approved, bioidentical progesterone (used when progesterone is indicated for endometrial protection).
• Non‑bioidentical examples: Premarin (conjugated equine estrogens) and Provera (medroxyprogesterone acetate) — commonly used, well‑studied but chemically different from human hormones.
• Compounded BHRT: many compounding pharmacies provide customized creams/gels/pills. If a compounded product is considered, use a reputable, accredited compounding pharmacy (look for Pharmacy Compounding Accreditation Board/PCAB accreditation or state board oversight). Example of a widely known compounding supplier: Wedgewood Pharmacy (note: names are examples — check current accreditation and reviews).

What major organizations say

• The FDA and the North American Menopause Society (NAMS) advise caution about compounded “bioidentical” products because they lack the same regulatory oversight and clinical testing as approved therapies. They recommend FDA‑approved formulations when possible.

Practical next steps

• Talk with a clinician experienced in menopause care (gynecologist, endocrinologist, or a NAMS‑certified menopause practitioner). The NAMS website has a provider directory and patient resources.
• Discuss your symptoms, medical history, family history (especially breast cancer, clotting, cardiovascular disease), and goals of therapy.
• Ask about options that match your risk profile (for example, transdermal estradiol + micronized progesterone if that fits your needs).
• Avoid relying on commercial saliva hormone testing to decide dosing; follow symptom response and appropriate lab tests ordered by your clinician.

If you’d like, tell me:

• Are you asking for menopause (estrogen/progesterone) HRT, testosterone therapy, or another situation?
• Any medical history or risk factors (e.g., past blood clots, breast cancer, heart disease)? I can then give more tailored information and list suitable FDA‑approved options and what to ask your prescriber.